Investment
Features
FeesSafety
Academy
More
Pluang+

Syndax's axatilimab fails primary endpoint in IPF trial but remains promising for cGVHD treatment

Company Fundamentals
12 Oct 2026
GlobeNewsWire
View Source
Bearish
Syndax's axatilimab fails primary endpoint in IPF trial but remains promising for cGVHD treatment

Syndax Pharmaceuticals announced that its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of reducing lung function decline. Despite this, axatilimab was well tolerated with a safety profile similar to placebo and no new safety concerns. Syndax will not pursue further development of axatilimab for IPF but continues to advance the drug in trials for chronic graft-versus-host disease (cGVHD), where it has shown promising results. Upcoming trial results for cGVHD are expected later this year and in early 2028, supporting continued focus on this indication.

Syndax Pharmaceuticals' axatilimab trial results come as 66 of 128 Health-sector US stocks on Pluang rose while 61 fell. For readers following Health-sector stocks, here is Pluang's market snapshot as of Oct 13, 2026 03:02 WIB: Sana Biotechnology Inc (SANA) traded at USD 2.62 with a 1-day change of -6.09% and a typical hold time of 24 days, Tilray Brands Inc (TLRY) at USD 3.35 with -5.23% change and 31 days hold time, and Twist Bioscience Corp (TWST) at USD 151.54 with -5.16% change and 27 days hold time. Pluang order activity showed strong buy interest in these names, notably 89% buy for SANA and 99% buy for TLRY.

More News

Bureau Veritas reports share buyback activity from October 5-9, 2026.

Bureau Veritas reports share buyback activity from October 5-9, 2026.

Bureau Veritas disclosed its share buyback transactions conducted between October 5 and October 9, 2026. This activity reflects the company's ongoing efforts to manage its capital structure and potentially enhance shareholder value. Investors should ...

Company Fundamentals
Neutral
1 hour ago
TRON reports $2.21T stablecoin settlement in Q3 2026 amid growing network activity and ecosystem expansion

TRON reports $2.21T stablecoin settlement in Q3 2026 amid growing network activity and ecosystem expansion

In Q3 2026, TRON DAO reported a milestone of $2.21 trillion in stablecoin settlements, with the network surpassing $30 trillion in cumulative transaction volume. The active user base grew by nearly 10%, and stablecoin supply increased to $93.88 billi...

Market News
Bullish
1 hour ago
Bureau Veritas reports treasury shares transactions from Oct 5-9, 2026.

Bureau Veritas reports treasury shares transactions from Oct 5-9, 2026.

Bureau Veritas disclosed its treasury shares transactions conducted between October 5 and October 9, 2026. This update is part of the company's regular reporting obligations to inform investors about changes in its treasury shares holdings. Such disc...

Company Fundamentals
Neutral
1 hour ago
New crypto Pepeto goes live on CoinMarketCap, signaling an imminent Binance listing and Cardano price target of $5.

New crypto Pepeto goes live on CoinMarketCap, signaling an imminent Binance listing and Cardano price target of $5.

Pepeto, a new Ethereum-based cryptocurrency, has launched its page on CoinMarketCap, indicating a Binance listing is near. The project features a working bridge across Ethereum, BNB Chain, and Solana, with zero-cost token transfers and AI contract ch...

Market News
Bullish
3 hours ago
Crédit Agricole to acquire IKB Deutsche Industriebank, boosting its German market presence.

Crédit Agricole to acquire IKB Deutsche Industriebank, boosting its German market presence.

Crédit Agricole has signed an agreement to acquire 100% of IKB Deutsche Industriebank, a key financier for Germany's Mittelstand companies. This acquisition strengthens Crédit Agricole's expansion in Germany, Europe's largest economy, aligning with i...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App